---
title: Side-by-side comparison of Sinovac's Efficacy
issues: "20005"
labels: Featured
tags:
  - Coronavirus
  - Vaccine
  - Sinovac
publishDate: 2020-12-27T15:20:34.725Z
author: 
description: "Comparing Sinovac's Phase 3 trial results with Pfizer and Moderna"
slug: "comparing-the-sinovac-vaccine-issue-20005"
---

<router-view name="sinovacDoughnuts" />


pfizer phase 3:
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
https://www.pfizer.com/science/coronavirus/vaccine
BNT162b2 to be 95% 
45,302 enrolled
43,125 second jab

or I can do age breakdown
or both



janssen phase 3:
https://www.jnj.com/our-company/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-in-the-us
60,000 adults 18 years old and older, including significant representation from those who are over age 60.
2 jabs
